Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.65 |
| ▸ | HCAR3 | P49019 | 3/20 | 0.60 |
| ▸ | MAPT | P10636 | 6/20 | 0.56 |
| ▸ | LMNA | P02545 | 5/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.56 |
| ▸ | WNK1 | Q9H4A3 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.56 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | CRHBP | P24387 | 1/20 | 0.49 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.49 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7182042 | 1.00 | MEN1 (0.65) | MEN1KMT2AL3MBTL1HCAR3MAPT | |
| SCHEMBL7187372 | 0.99 | MEN1 (0.67) | MEN1KMT2AL3MBTL1HCAR3MAPT | |
| SCHEMBL20333669 | 0.96 | KMT2A (0.63) | MEN1KMT2AL3MBTL1HCAR3MAPT | |
| SCHEMBL8248585 | 0.93 | HCAR3 (0.59) | MEN1KMT2AL3MBTL1HCAR3MAPT | |
| SCHEMBL7185675 | 0.88 | KMT2A (0.53) | MEN1KMT2AL3MBTL1HCAR3MAPT | |
| SCHEMBL7179403 | 0.87 | HCAR3 (0.53) | MEN1KMT2AL3MBTL1HCAR3MAPT | |
| SCHEMBL7185961 | 0.87 | HCAR3 (0.56) | MEN1KMT2AL3MBTL1HCAR3MAPT | |
| SCHEMBL7185959 | 0.87 | HCAR3 (0.56) | MEN1KMT2AL3MBTL1HCAR3MAPT | |
| SCHEMBL7179398 | 0.87 | HCAR3 (0.53) | MEN1KMT2AL3MBTL1HCAR3MAPT | |
| SCHEMBL7183457 | 0.86 | HCAR3 (0.52) | MEN1KMT2AL3MBTL1HCAR3MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7511145-B2 | Bicyclic heteroaryl derivatives | GENELABS TECHNOLOGIES, INC. (US) | 2009-03-31 | — | — | US | disclosed |
| US-7511145-B2 | Bicyclic heteroaryl derivatives | GENELABS TECHNOLOGIES, INC. (US) | 2009-03-31 | — | — | US | disclosed |
| US-7511145-B2 | Bicyclic heteroaryl derivatives | GENELABS TECHNOLOGIES, INC. (US) | 2009-03-31 | — | — | US | disclosed |
| US-20090081165-A1 | BICYCLIC HETEROARYL DERIVATIVES | GENELABS TECHNOLOGIES, INC. | 2009-03-26 | — | — | US | disclosed |
| US-20090081165-A1 | BICYCLIC HETEROARYL DERIVATIVES | GENELABS TECHNOLOGIES, INC. | 2009-03-26 | — | — | US | disclosed |
| EP-1651631-A1 | BICYCLIC IMIDAZOL DERIVATIVES AGAINST FLAVIVIRIDAE | GENELABS TECHNOLOGIES, INC. (US) | 2006-05-03 | — | — | EP | disclosed |
| US-20050187390-A1 | Bicyclic heteroaryl derivatives | GENELABS TECHNOLOGIES, INC. | 2005-08-25 | — | — | US | disclosed |
| WO-2005012288-A1 | BICYCLIC IMIDAZOL DERIVATIVES AGAINST FLAVIVIRIDAE | GENELABS TECHNOLOGIES, INC (US) | 2005-02-10 | — | — | WO | disclosed |
| EP-1429759-A4 | COMPOUNDS USEFUL FOR TREATING HEPATITUS C VIRUS | BRISTOL MYERS SQUIBB CO (US) | 2004-12-15 | — | — | EP | disclosed |
| US-6803374-B2 | INHIBIT THE RNA-DEPENDENT RNA POLYMERASE (RDRP) ENCODED BY HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY | 2004-10-12 | — | — | US | disclosed |
| EP-1429759-A2 | COMPOUNDS USEFUL FOR TREATING HEPATITUS C VIRUS | Bristol-Myers Squibb Company (US) | 2004-06-23 | — | — | EP | disclosed |
| US-20030134853-A1 | Compounds useful for treating hepatitis C virus | BRISTOL-MYERS SQUIBB COMPANY | 2003-07-17 | — | — | US | disclosed |
| US-6582351-B1 | Benzimidazole heterocyclic compounds having pharmacological activities, and their use as a medicament for treatment or prevention of diseases mediated by cGMP-PDE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-06-24 | — | — | US | disclosed |
| WO-2003026587-A2 | COMPOUNDS USEFUL FOR TREATING HEPATITUS C VIRUS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-04-03 | — | — | WO | disclosed |
| EP-0315959-B1 | Quinoxaline compounds and their preparation and use | NOVO NORDISK AS (DK) | 1994-03-02 | — | — | EP | disclosed |
| US-5026704-A | Neuroleptic agent, quisqualate-antagonist | NOVO NORDISK A/S (DK) | 1991-06-25 | — | — | US | disclosed |
| US-4948794-A | NEUROLEPTIC AGENTS | A/S FERROSAN (DK) | 1990-08-14 | — | — | US | disclosed |
| EP-0315959-A2 | Quinoxaline compounds and their preparation and use | NOVO NORDISK A/S (DK) | 1989-05-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090081165-A1 | BICYCLIC HETEROARYL DERIVATIVES | HAVCR2, MAVS, ZC3HAV1 | MEN1 4832/4885KMT2A 2410/4885L3MBTL1 1221/4885 |
| US-20050187390-A1 | Bicyclic heteroaryl derivatives | HAVCR2, MAVS, ZC3HAV1 | MEN1 4832/4885KMT2A 2410/4885L3MBTL1 1221/4885 |
| US-20030134853-A1 | Compounds useful for treating hepatitis C virus | OAT, HAVCR2, GOT1 | MEN1 3281/4885KMT2A 4468/4885L3MBTL1 1110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.